In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug July 8, 2021 Auto Bot Aduhelm (Drug), alzheimer's disease, Biogen Inc, Clinical Trials, Food and Drug Administration, Labeling and Labels (Product) 0 The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.